Chand Raja

University of Washington — United States

Medicine · Health Sciences

16h-index785citations25works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Radiopharmaceutical Chemistry and Applications(13), Body Composition Measurement Techniques(7), Nutrition and Health in Aging(6), Monoclonal and Polyclonal Antibodies Research(4), Thermoregulation and physiological responses(4)

Publications25 total

Analysis of Treatment Modalities for Gastric Adenocarcinoma
International Journal of Radiation Oncology*Biology*Physics·2012· 2 citedOpen Access
Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models By 213Bilabeled Multiple Targeted α Radioimmunoconjugates
Clinical Cancer Research·2009· 25 cited
Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205 / Bismuth-206
Cancer Biology & Therapy·2008· 24 citedOpen Access
New Directions for Clinical Trials of Targeted Alpha Therapy for Metastatic Melanoma
Current Radiopharmaceuticals·2008· 9 cited
Bismuth-213 radioimmunotherapy with C595 anti–MUC1 monoclonal antibody in an ovarian cancer ascites model
Cancer Biology & Therapy·2008· 50 citedOpen Access
The cytokinesis-block micronucleus assay as a biological dosimeter for targeted alpha therapy
Physics in Medicine and Biology·2007· 31 cited
Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer
Physics in Medicine and Biology·2007· 39 cited
Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma
Cancer Biology & Therapy·2007· 107 cited
Pharmacokinetics and toxicity of 213Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer
Cancer Biology & Therapy·2007· 28 citedOpen Access
P-16 Regression of melanoma by tumour anti-vascular alpha therapy
Melanoma Research·2007
Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model
Cancer Biology & Therapy·2006· 20 cited
Intralesional targeted alpha therapy for metastatic melanoma
Cancer Biology & Therapy·2005· 121 citedOpen Access
Pre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer
Clinical & Experimental Metastasis·2005· 46 cited
In vivo studies of pharmacokinetics and efficacy of bismuth-213 labeled antimelanoma monoclonal antibody 9.2.27
Cancer Biology & Therapy·2005· 17 citedOpen Access
Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters
Cancer Letters·2005· 36 cited
Hip girth as a predictor of abdominal adiposity in postmenopausal women
Nutrition·2004· 7 cited
Targeted alpha therapy for cancer
Physics in Medicine and Biology·2004· 60 cited
Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin α-conjugate
Cancer Letters·2004· 25 cited
Total Body Protein in Chronic Diseases and in Aging
Annals of the New York Academy of Sciences·2000· 26 cited
Determination of skeletal muscle and fat-free mass by nuclear and dual-energy X-ray absorptiometry methods in men and women aged 51–84 y
American Journal of Clinical Nutrition·1999· 88 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Barry Allen(18), Syed Rizvi(14), Christos Apostolidis(11), Emma Song(11), Yong Li(9), Chang Qu(9), Aliyah Morgenstern(8), John H. Kearsley(6), Peter Graham(5), Raghbir Singh(5), Ralph A. Reisfeld(3), Alfred Morgenstern(3), Julia Beretov(3), Wendy Tsui(2), John A. Thompson(2), John F. Thompson(2), Ross C. Smith(2), Alan C. Perkins(2), Yan Song(2), Syed Meraj Azhar Rizvi(2)